Glenmark’s PMS study allays concerns on use of Favipiravir for Covid-19 treatment
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The company reports revenue growth of 26% and PAT growth of 21% YoY
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
The study was conducted in patients with mild to moderate COVID-19
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Subscribe To Our Newsletter & Stay Updated